Medicare’s Drug-Pricing Proposal Carries A Hidden Cost

Aug 10, 2026 07:00 PM - 1 hour ago 1

The Trump management says it wants to accelerate aesculapian innovation. Yet 1 caller proposal from the Centers for Medicare and Medicaid Services could do conscionable the opposite.

The agency has projected a seemingly method description of Medicare’s medicine supplier value power scheme, which was created by the Inflation Reduction Act of 2022. CMS wants to dainty definite newer medicines arsenic though they were the aforesaid merchandise arsenic older ones erstwhile determining erstwhile they go eligible for authorities value controls.

That alteration would person real-world consequences. It would shorten the play companies person to retrieve investments successful improving existing medicines. As the expected return connected those investments falls, companies will person little logic to prosecute them.

Pharmaceutical invention seldom ends pinch a drug’s first support from the Food and Drug Administration. Researchers routinely walk years uncovering amended ways to usage medicines that already work—developing caller formulations, improving transportation methods, and discovering caller uses for existing therapies.

One study recovered that nearly 4 successful ten caller tablet and capsule medicines were later followed by astatine slightest 1 FDA-approved caller formulation.

Those improvements return years of further research, caller objective trials, different information of FDA review, and important financial investment.

Cancer attraction offers 1 of the clearest examples. Opdivo, Bristol Myers Squibb’s immunotherapy for respective cancers, was primitively disposable only arsenic an intravenous infusion. In precocious 2024, the FDA approved Opdivo Qvantig, a caller formulation that combines nivolumab pinch hyaluronidase, allowing galore patients to person the aforesaid medicine arsenic a three- to five-minute injection nether the tegument alternatively than a 30-minute IV infusion.

Patients walk little clip successful infusion chairs. And physicians and nurses tin dainty much people. One study estimated that the caller formulation reduced mentation and management clip by much than 63% and nonstop supplier costs by 17% per curen section compared pinch the intravenous version.

These gains required sizeable post-approval work, including a Phase 3 proceedings involving 495 patients and a separate FDA review for the caller formulation.

Innovations for illustration Opdivo Qvantig are precisely what CMS is putting astatine risk. Under current policy, separately approved medicines mostly person their ain timeline for imaginable action for Medicare’s value controls. Small-molecule narcotics mostly cannot beryllium selected until at slightest 7 years aft FDA approval, while biologics cannot beryllium selected until at slightest 11 years after.

CMS now proposes treating definite separately approved medicines that stock an progressive constituent pinch an older merchandise arsenic though they were a azygous “qualifying azygous root drug,” aliases QSSD, for purposes of Medicare’s price-control program. As a result, immoderate newer therapies could go eligible for authorities value controls years sooner than they different would.

CMS defends this attack by arguing that medicines sharing an progressive constituent should beryllium treated alike. But companies don’t put successful follow-on investigation based solely connected chemistry. They put erstwhile they expect the return will warrant the cost. If Medicare shortens the play earlier value controls apply, that calculation changes. Projects that erstwhile made financial consciousness nary longer will.

Skeptics whitethorn disregard this interest arsenic speculative. It isn’t. Drugmakers person already begun adjusting finance decisions successful consequence to the Inflation Reduction Act. Just months aft the rule passed, Eli Lilly abandoned improvement of LOXO-338, an experimental curen for definite humor cancers. A company spokesperson explained that, “in ray of the Inflation Reduction Act, this programme nary longer met our period for continued investment.”

Broader investigation points successful the aforesaid direction. University of Chicago economists Tomas Philipson and Troy Durie estimate that the law’s pricing provisions could consequence successful astir 135 fewer caller medicines being developed complete the adjacent 2 decades.

Every regularisation creates incentives. CMS’s connection would promote 1 point supra each else: investing little successful improving existing medicines. That’s a costly tradeoff for patients—and 1 Medicare shouldn’t make.